ARTICLE | Clinical News
ARQ 197: SPA received
October 18, 2010 7:00 AM UTC
ArQule received an SPA from FDA for a planned double-blind Phase III trial to evaluate ARQ 197 plus Tarceva erlotinib in patients with locally advanced or metastatic NSCLC of non-squamous histology. ...